MLTX NASDAQ
MoonLake Immunotherapeutics
1W: +21.1%
1M: -1.9%
3M: -36.9%
YTD: -1.2%
1Y: +24.8%
3Y: -79.0%
5Y: +18.1%
$11.95
+0.14 (+1.14%)
After Hours: $11.84 (-0.11, -0.88%)
Weekly Expected Move ±10.7%
$9
$11
$12
$13
$14
Credit Risk of going bust: higher than 60% of companies Debt: 9.2% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.16 (down 99%), MoonLake Immunotherapeutics would be worth roughly what it owes.
Total debt $101.5M against a stock market value of $1.01B.
Distance to default 4.27 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $49.8M (short-term plus half of long-term), stock volatility 70.4%; Altman Z'' 2.73. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $101.5M against a stock market value of $1.01B.
Distance to default 4.27 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $49.8M (short-term plus half of long-term), stock volatility 70.4%; Altman Z'' 2.73. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.0B
52W Range9.37-23.29
Volume1,511,233
Avg Volume1,569,492
Beta1.08
Dividend—
Analyst Ratings
Company Info
CEOJorge Santos da Silva
Employees130
SectorHealthcare
IndustryBiotechnology
IPO Date2020-10-20
Websitemoonlaketx.com
Dorfstrasse 29
Zug, ZG 6300
CH
Zug, ZG 6300
CH
41 415108022
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.
Latest News
MoonLake Soars 18% as Rival AbbVie’s Skin Disease Trial Data “Underwhelms”
MLTX Nov 2026 10.000 call (MLTX261120C00010000) stock historical prices and data - Yahoo Finance UK
MLTX Nov 2026 26.000 call (MLTX261120C00026000) stock price, news, quote and history - Yahoo Finance UK
MLTX Nov 2026 27.000 call (MLTX261120C00027000) stock price, news, quote and history - Yahoo Finance UK
MLTX Nov 2026 32.000 call (MLTX261120C00032000) stock price, news, quote and history - Yahoo Finance UK
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Reich Kristian | S-Sale | 1,100 | $20.00 | 2026-07-27 |
| Reich Kristian | S-Sale | 2,448 | $20.00 | 2026-07-22 |
| Reich Kristian | S-Sale | 50,000 | $20.02 | 2026-07-21 |
| Reich Kristian | S-Sale | 43,700 | $20.09 | 2026-07-20 |
| Reich Kristian | S-Sale | 16,105 | $20.01 | 2026-07-15 |